{"log_id": 7186907697923375048, "direction": 0, "words_result_num": 46, "words_result": [{"probability": {"variance": 3.6e-05, "average": 0.998467, "min": 0.962816}, "location": {"width": 850, "top": 166, "height": 30, "left": 219}, "words": "同时接受胰岛素治疗或口服降糖药物的糖尿病患者有症状性低血糖的报道。一些单胺氧化酶"}, {"probability": {"variance": 4e-06, "average": 0.999035, "min": 0.989961}, "location": {"width": 848, "top": 201, "height": 31, "left": 220}, "words": "抑制剂与接受胰岛素或降糖药物的糖尿病患者的低血糖发作有联系。虽然使用利奈唑胺与低"}, {"probability": {"variance": 9.7e-05, "average": 0.997782, "min": 0.937541}, "location": {"width": 830, "top": 235, "height": 31, "left": 216}, "words": "血糖的因果关系并未建立,但是应警告糖尿病患者使用利奈唑胺时可能发生的低血糖反应"}, {"probability": {"variance": 0.000112, "average": 0.996741, "min": 0.940901}, "location": {"width": 854, "top": 270, "height": 27, "left": 215}, "words": "如果低血糖发生,应降低胰岛素或口服降糖药的剂量,或停止口服降糖药、胰岛素或利奈唑"}, {"probability": {"variance": 0, "average": 0.999562, "min": 0.998413}, "location": {"width": 86, "top": 304, "height": 23, "left": 215}, "words": "胺的治疗"}, {"probability": {"variance": 0.000876, "average": 0.98433, "min": 0.925138}, "location": {"width": 111, "top": 338, "height": 25, "left": 236}, "words": "般注意事项"}, {"probability": {"variance": 0, "average": 0.999768, "min": 0.999159}, "location": {"width": 130, "top": 370, "height": 25, "left": 254}, "words": "乳酸性酸中毒"}, {"probability": {"variance": 3.4e-05, "average": 0.997612, "min": 0.965197}, "location": {"width": 816, "top": 401, "height": 33, "left": 254}, "words": "应用利奈唑胺过程中,有乳酸性酸中毒的报道。在报道的病例中,病人反复出现恶心和"}, {"probability": {"variance": 8e-06, "average": 0.998668, "min": 0.986932}, "location": {"width": 857, "top": 436, "height": 29, "left": 213}, "words": "呕吐。患者在接受利奈唑胺时,如发生反复恶心或呕吐、腹痛、有原因不明的酸中毒、低碳"}, {"probability": {"variance": 2e-06, "average": 0.99917, "min": 0.993403}, "location": {"width": 857, "top": 469, "height": 29, "left": 212}, "words": "酸血症或换气过度,需要立即进行临床检查。如果出现乳酸性酸中毒,应针对潜在风险权衡"}, {"probability": {"variance": 0.000193, "average": 0.993196, "min": 0.949881}, "location": {"width": 235, "top": 502, "height": 26, "left": 212}, "words": "继续使用利奈唑胺的益处"}, {"probability": {"variance": 0, "average": 0.999595, "min": 0.999037}, "location": {"width": 153, "top": 536, "height": 26, "left": 251}, "words": "线粒体功能障碍"}, {"probability": {"variance": 2.4e-05, "average": 0.997605, "min": 0.975457}, "location": {"width": 817, "top": 568, "height": 31, "left": 253}, "words": "利奈唑胺可抑制线粒体蛋白合成。该抑制作用可能导致不良事件,如乳酸性酸中毒、贫"}, {"probability": {"variance": 1.1e-05, "average": 0.998626, "min": 0.978439}, "location": {"width": 860, "top": 602, "height": 29, "left": 211}, "words": "血和神经病变(视神经病变和周围神经病变);这些事件在使用药物超过28天的情况下较常"}, {"probability": {"variance": 0, "average": 0.999924, "min": 0.999924}, "location": {"width": 24, "top": 635, "height": 23, "left": 211}, "words": "见"}, {"probability": {"variance": 0.008214, "average": 0.962178, "min": 0.722513}, "location": {"width": 151, "top": 667, "height": 26, "left": 247}, "words": "5-羟色胺综合征"}, {"probability": {"variance": 0.002901, "average": 0.984797, "min": 0.6916}, "location": {"width": 822, "top": 698, "height": 32, "left": 247}, "words": "利奈唑胺合用5-羟色胺类药物,包括抗抑郁药,如:选择性5-羟色胺再摄取抑制剂"}, {"probability": {"variance": 5e-05, "average": 0.996354, "min": 0.958533}, "location": {"width": 807, "top": 731, "height": 30, "left": 258}, "words": "Rs),患者中有关于5-羟色胺综合征的自发性报告(见【注意事项】中的药物相互作用)。"}, {"probability": {"variance": 0.000144, "average": 0.994428, "min": 0.948562}, "location": {"width": 559, "top": 764, "height": 27, "left": 208}, "words": "因此,利奈唑胺禁止与5-羟色胺类药物合用(参见【禁忌】)"}, {"probability": {"variance": 0.005662, "average": 0.969478, "min": 0.611527}, "location": {"width": 821, "top": 796, "height": 32, "left": 247}, "words": "除非临床上合适并且密切监测患者是否出现5-羟色胺综合征或恶性综合征样(NMS-like)"}, {"probability": {"variance": 0.002635, "average": 0.988667, "min": 0.666572}, "location": {"width": 861, "top": 830, "height": 28, "left": 206}, "words": "反应的相关体征和或症状,否则利奈唑胺不可用于类癌综合征和/或应用以下药物的患者:5"}, {"probability": {"variance": 0.000245, "average": 0.993325, "min": 0.923457}, "location": {"width": 866, "top": 861, "height": 32, "left": 204}, "words": "羟色胺再摄取抑制剂、三环抗抑郁药、5-羟色胺5-HT1受体激动剂(曲普坦类)、哌替啶、安"}, {"probability": {"variance": 6e-06, "average": 0.998416, "min": 0.992344}, "location": {"width": 172, "top": 894, "height": 25, "left": 205}, "words": "非他酮或丁螺环酮"}, {"probability": {"variance": 0.001088, "average": 0.990022, "min": 0.794377}, "location": {"width": 827, "top": 927, "height": 29, "left": 243}, "words": "当临床上利奈唑胺需与5-羟色胺类药物合用时,应密切观察患者是否出现5羟色胺综合征"}, {"probability": {"variance": 8e-06, "average": 0.997933, "min": 0.987004}, "location": {"width": 865, "top": 959, "height": 30, "left": 204}, "words": "的症状和体征,如认知障碍、高热、反射亢进和共济失调。如果出现了上述体征或症状,医"}, {"probability": {"variance": 5.6e-05, "average": 0.996288, "min": 0.972486}, "location": {"width": 411, "top": 990, "height": 27, "left": 203}, "words": "生应考虑停用其中1种药物或2种药物均停用"}, {"probability": {"variance": 0.004153, "average": 0.98479, "min": 0.595444}, "location": {"width": 830, "top": 1024, "height": 29, "left": 241}, "words": "在某些情况下,已接受5-羟色胺类抗抑郁药或丁螺环酮的患者可能需要使用利奈唑胺紧"}, {"probability": {"variance": 8.5e-05, "average": 0.996613, "min": 0.940536}, "location": {"width": 869, "top": 1056, "height": 28, "left": 201}, "words": "急治疗。如果没有利奈唑胺替代药物可用且应用利奈唑胺的潜在益处大于5-羟色胺综合征或"}, {"probability": {"variance": 0.003416, "average": 0.977302, "min": 0.739172}, "location": {"width": 865, "top": 1087, "height": 28, "left": 201}, "words": "NMS-like反应的风险,应立即停用5-羟色胺类抗抑郁药并使用利奈唑胺。患者应接受两周(如"}, {"probability": {"variance": 0.00537, "average": 0.985686, "min": 0.516993}, "location": {"width": 870, "top": 1121, "height": 28, "left": 200}, "words": "使用氟西汀则为五周)监测或直到最后一剂利奈唑胺24小时后,以较早者为准。5-羟色胺综"}, {"probability": {"variance": 0.003717, "average": 0.981375, "min": 0.717468}, "location": {"width": 868, "top": 1154, "height": 28, "left": 199}, "words": "合征或NMS- -like5反应的症状包括高热、强直、肌阵挛、自主神经功能紊乱和精神状态改变(包"}, {"probability": {"variance": 0.000307, "average": 0.995399, "min": 0.89644}, "location": {"width": 739, "top": 1185, "height": 28, "left": 198}, "words": "括极度激越并发展为谵妄和昏迷)。应当对患者的抗抑郁药停药症状进行监测"}, {"probability": {"variance": 6.6e-05, "average": 0.99783, "min": 0.949259}, "location": {"width": 830, "top": 1219, "height": 29, "left": 239}, "words": "如果出现了上述体征或症状,医生应考虑停用其中一种药物或两种药物均停用;如果停"}, {"probability": {"variance": 2.9e-05, "average": 0.996773, "min": 0.978267}, "location": {"width": 723, "top": 1252, "height": 28, "left": 197}, "words": "用5羟色胺类药物,可出现停药症状(其相关的停药症状见该药物的说明书)"}, {"probability": {"variance": 1.4e-05, "average": 0.997925, "min": 0.986577}, "location": {"width": 240, "top": 1284, "height": 26, "left": 237}, "words": "周围神经病和视神经病变"}, {"probability": {"variance": 3e-06, "average": 0.999323, "min": 0.991224}, "location": {"width": 830, "top": 1317, "height": 28, "left": 235}, "words": "在利奈唑胺治疗的患者中有周围神经病、视神经病变和视神经炎的报道,主要为治疗时"}, {"probability": {"variance": 0, "average": 0.999586, "min": 0.997916}, "location": {"width": 867, "top": 1350, "height": 27, "left": 197}, "words": "间超过了28天的最长推荐疗程的患者。在视神经病变进展至视觉丧失的病例中,患者治疗时"}, {"probability": {"variance": 5e-06, "average": 0.998831, "min": 0.990442}, "location": {"width": 791, "top": 1383, "height": 27, "left": 194}, "words": "间超过了最长的推荐疗程。在利奈唑胺治疗小于28天的患者中,有视力模糊的报道"}, {"probability": {"variance": 7e-06, "average": 0.999068, "min": 0.983704}, "location": {"width": 832, "top": 1417, "height": 27, "left": 233}, "words": "如患者出现视力损害的症状,如:视敏度改变、色觉改变、视力模糊或视野缺损,应及"}, {"probability": {"variance": 8e-06, "average": 0.997949, "min": 0.985849}, "location": {"width": 877, "top": 1449, "height": 30, "left": 191}, "words": "时进行眼科检查。对于所有长期(大于等于3个月)应用利奈唑胺的患者及报告有新的视觉"}, {"probability": {"variance": 0.000135, "average": 0.995799, "min": 0.927304}, "location": {"width": 874, "top": 1482, "height": 30, "left": 190}, "words": "症状的患者,不论其接受利奈唑胺治疗时间的长短,均应当进行视觉功能监测。如发生周围"}, {"probability": {"variance": 0, "average": 0.999797, "min": 0.998713}, "location": {"width": 762, "top": 1514, "height": 29, "left": 190}, "words": "神经病和视神经病变,应进行用药利益与潜在风险的评价,以判断是否继续用药"}, {"probability": {"variance": 8e-06, "average": 0.999183, "min": 0.982439}, "location": {"width": 868, "top": 1547, "height": 30, "left": 229}, "words": "目前正在使用或最近使用过抗分支杆菌药物治疗肺结核的患者,如果同时使用利奈唑胺"}, {"probability": {"variance": 0.001402, "average": 0.977594, "min": 0.878317}, "location": {"width": 150, "top": 1608, "height": 21, "left": 552}, "words": "第14页,共29页"}, {"probability": {"variance": 0.008037, "average": 0.94035, "min": 0.760043}, "location": {"width": 113, "top": 1634, "height": 22, "left": 567}, "words": "辉瑞——机密"}, {"probability": {"variance": 6e-06, "average": 0.997102, "min": 0.990879}, "location": {"width": 77, "top": 1657, "height": 20, "left": 280}, "words": "20160525"}], "language": 3}